Novartis‘ siponimod (BAF312) can reduce blood levels of a biomarker of nerve cell damage in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical trial shows.
Researchers will present the latest results of the ongoing trial at the 2018 annual meeting of the American Academy of Neurology in Los Angeles, April 21-27. The presentation will be titled “Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients.”
Read more- https://multiplesclerosisnewstoday.c...e6abe-72871989
Can we be hopeful that siponimod can reduce SPMS activity??
Researchers will present the latest results of the ongoing trial at the 2018 annual meeting of the American Academy of Neurology in Los Angeles, April 21-27. The presentation will be titled “Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients.”
Read more- https://multiplesclerosisnewstoday.c...e6abe-72871989
Can we be hopeful that siponimod can reduce SPMS activity??